secwatch.observer — SEC 8-K summary
======================================

Issuer:     PALVELLA THERAPEUTICS, INC. (PVLA)
CIK:        0001583648
Form:       8-K
Filed at:   2023-03-29T23:59:59+00:00
Accession:  0001437749-23-008303
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pieris Pharma reports FY2022 net loss $33.3M; cash down to $59.2M; elarekibep data delayed to mid-2024
--------------------------------------------------------------------------------

- Net loss $33.3M ($0.45/share) vs $45.7M ($0.71) in 2021; R&D expense fell to $53.0M from $66.7M.
- Cash, cash equivalents and investments $59.2M at Dec 31, 2022, down from $117.8M; company funded for >12 months.
- Elarekibep Phase 2a asthma data now expected mid-2024; AstraZeneca adding >100 sites to complete trial.
- PRS-220 Phase 1 IPF topline results expected H2 2023; PRS-400 advancing toward candidate nomination in 2023.
- Seagen initiated Phase 1 for SGN-BB228, triggering $5M milestone; Servier discontinued PRS-352.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1583648/000143774923008303/0001437749-23-008303-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1583648/000143774923008303/pirs20221130_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-008303

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer